TotalMarketCap

Kymera Therapeutics

KYMRNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$10.837 B

$126.95 -6.83%

Close of 6 Nov 2026

As of 6 Nov 2026, Kymera Therapeutics (KYMR) has a market capitalization of $10.8B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$39.2M

#2792 by revenue

Earnings

$311.4M

#814 by earnings

Shares outstanding

85,371,397

Latest filing cover page

P/E ratio

34.8

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #10Halozyme TherapeuticsHALO$14.0B
  2. #11Bio-TechneTECH$11.4B
  3. #12Kymera TherapeuticsKYMR$10.8B
  4. #13RepligenRGEN$10.8B
  5. #14QiagenQGEN$10.5B

What if Kymera Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$330,753.33

Per share 2,605× higher

Bitcoin $1.53T

$17,896.49

Per share 141× higher

Apple $5.02T

$58,752.50

Per share 463× higher

Or at a round number

$20.0B$50.0B$100.0B$200.0B

Where these numbers come from

Share counts and financials for Kymera Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.